Delcath Systems Q3 2026 Earnings Date & Estimates

Delcath Systems (NASDAQ:DCTH) is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand. The company’s technology is based on percutaneous hepatic perfusion, in which the liver is temporarily isolated from the general circulation so that chemotherapy can be administered directly to the organ and then filtered before the blood returns to the body. Delcath serves hospitals and cancer treatment centers in the United States and selected international markets, including Europe.